Active Ingredient History
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. It marketed in the United States, the European Union, and in other countries by Schering-Plough under the trade name Noxafil. Noxafil is used for prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane. This may be responsible for the antifungal activity of posaconazole. It is absorbed within three to five hours and predominately eliminated through the liver, and has a half-life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Aplastic (Phase 4)
Aspergillosis (Phase 4)
Aspergillus (Phase 3)
Bone Marrow Transplantation (Phase 4)
Brain Neoplasms (Early Phase 1)
Candidemia (Phase 3)
Candidiasis, Invasive (Phase 4)
Candidiasis, Oral (Phase 3)
Chagas Disease (Phase 2)
Coccidioidomycosis (Phase 3)
Crohn Disease (Phase 4)
Cystic Fibrosis (Phase 2/Phase 3)
Drugs, Investigational (Phase 4)
Fungemia (Phase 3)
Glioblastoma (Early Phase 1)
Glioma (Early Phase 1)
Graft vs Host Disease (Phase 4)
Granulomatous Disease, Chronic (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 4)
HIV Infections (Phase 3)
Infections (Phase 4)
Invasive Fungal Infections (Phase 4)
Invasive Pulmonary Aspergillosis (Phase 3)
Job Syndrome (Phase 3)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 1)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)
Leukopenia (Phase 3)
Lymphoma (Phase 1/Phase 2)
Mucormycosis (Phase 2)
Mycoses (Phase 4)
Mycosis Fungoides (Phase 4)
Myelodysplastic Syndromes (Phase 4)
Myeloproliferative Disorders (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neutropenia (Phase 4)
Obesity, Morbid (Phase 4)
Onychomycosis (Phase 2)
Pharmacokinetics (Phase 4)
Pneumocystis (Phase 3)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Risk Factors (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
